Equities research analysts predict that Check Cap Ltd (NASDAQ:CHEK) will report earnings of ($0.14) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Check Cap’s earnings. Check Cap reported earnings of ($0.15) per share in the same quarter last year, which would indicate a positive year over year growth rate of 6.7%. The firm is expected to issue its next quarterly earnings results on Thursday, March 8th.
On average, analysts expect that Check Cap will report full-year earnings of ($0.61) per share for the current year, with EPS estimates ranging from ($0.62) to ($0.60). For the next year, analysts anticipate that the business will post earnings of ($0.54) per share, with EPS estimates ranging from ($0.60) to ($0.48). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Check Cap.
Check Cap (NASDAQ:CHEK) last issued its quarterly earnings results on Monday, November 6th. The medical research company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.05.
CHEK has been the topic of a number of recent research reports. HC Wainwright boosted their price target on shares of Check Cap from $5.50 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, January 11th. Zacks Investment Research upgraded shares of Check Cap from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research note on Monday, January 15th.
Shares of Check Cap (NASDAQ CHEK) traded down $0.02 during trading hours on Thursday, reaching $0.87. 145,492 shares of the company’s stock were exchanged, compared to its average volume of 506,295. The stock has a market capitalization of $17.14, a price-to-earnings ratio of -1.43 and a beta of -0.68. Check Cap has a one year low of $0.80 and a one year high of $2.41.
A hedge fund recently raised its stake in Check Cap stock. Sabby Management LLC grew its holdings in shares of Check Cap Ltd (NASDAQ:CHEK) by 467.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,418,893 shares of the medical research company’s stock after purchasing an additional 1,169,061 shares during the period. Check Cap comprises about 0.1% of Sabby Management LLC’s portfolio, making the stock its 24th biggest position. Sabby Management LLC owned about 8.36% of Check Cap worth $2,724,000 at the end of the most recent quarter. 16.75% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Expect Check Cap Ltd (CHEK) to Post -$0.14 Earnings Per Share” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/01/zacks-analysts-expect-check-cap-ltd-chek-to-post-0-14-earnings-per-share.html.
Check Cap Company Profile
Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.
Get a free copy of the Zacks research report on Check Cap (CHEK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.